| James Richard Allman, MD | |
|
350 Hillcrest Dr, Suite 2, Ashland, OH 44805-4052 | |
| (419) 207-2513 | |
| (419) 207-2349 |
| Full Name | James Richard Allman |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 35 Years |
| Location | 350 Hillcrest Dr, Ashland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710980248 | NPI | - | NPPES |
| 0920767 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 60132 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospitals Samaritan Medical Center | Ashland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Primary Care Practices Inc | 3072417534 | 940 |
News Archive
Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.
New studies exploring breast cancer risk perceptions and use of radiotherapy and MRI for women with ductal carcinoma in situ (DCIS, a preinvasive form of breast cancer) were highlighted today in a virtual presscast in advance of the 2013 Breast Cancer Symposium.
Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.
A new study has shown that one in nine Australian patients who were hospitalized between 2012 and 2015, suffered from one or the other hospital acquired complication. These complications are usually of a preventable nature and occur when there is a deficiency in patient care.
› Verified 7 days ago
| Entity Name | University Primary Care Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003935339 PECOS PAC ID: 3072417534 Enrollment ID: O20031125000767 |
News Archive
Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.
New studies exploring breast cancer risk perceptions and use of radiotherapy and MRI for women with ductal carcinoma in situ (DCIS, a preinvasive form of breast cancer) were highlighted today in a virtual presscast in advance of the 2013 Breast Cancer Symposium.
Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.
A new study has shown that one in nine Australian patients who were hospitalized between 2012 and 2015, suffered from one or the other hospital acquired complication. These complications are usually of a preventable nature and occur when there is a deficiency in patient care.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Richard Allman, MD Po Box 72098, Cleveland, OH 44192-0002 Ph: (419) 207-2513 | James Richard Allman, MD 350 Hillcrest Dr, Suite 2, Ashland, OH 44805-4052 Ph: (419) 207-2513 |
News Archive
Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.
New studies exploring breast cancer risk perceptions and use of radiotherapy and MRI for women with ductal carcinoma in situ (DCIS, a preinvasive form of breast cancer) were highlighted today in a virtual presscast in advance of the 2013 Breast Cancer Symposium.
Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.
A new study has shown that one in nine Australian patients who were hospitalized between 2012 and 2015, suffered from one or the other hospital acquired complication. These complications are usually of a preventable nature and occur when there is a deficiency in patient care.
› Verified 7 days ago